Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
7 August 2019 Company to Host Conference Call Today at 9:00 AM AEST 7:00PM EDT (Tuesday, August 6th U.S) -Dial-in details posted at end of release Primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated statistically significant…
Read MoreAI Computer Generated Works and Copyright Protection
(posted 6th August 2019) Stephens Lawyers & Consultants have published an article which includes practical guidelines on steps that can be taken by businesses/companies to ensure that their AI generated works are protected by copyright. This is the…
Read MoreTiny blood cells could protect against cerebral palsy (WEHI)
2 August 2019 A Melbourne study supported by the Cerebral Palsy Alliance Research Foundation is following an exciting new lead that could help to protect newborn babies against cerebral palsy, the most common childhood disability in Australia. Platelets…
Read MoreFrontiers Program Feedback for next Round
1 August 2019 The successful applicants for the first round of the Frontiers Program were announced in April this year, and attention has now turned to the next round which is anticipated to open in October. While the…
Read More
